HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 274 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,702,838 | +22.2% | 254,001 | +15.4% | 0.01% | +50.0% |
| Q2 2023 | $7,939,404 | -5.0% | 220,111 | +0.6% | 0.00% | -20.0% |
| Q1 2023 | $8,357,041 | -33.6% | 218,828 | -1.0% | 0.01% | -37.5% |
| Q4 2022 | $12,586,566 | +34.3% | 221,117 | -6.7% | 0.01% | +14.3% |
| Q3 2022 | $9,369,869 | -14.6% | 237,010 | -4.0% | 0.01% | -12.5% |
| Q2 2022 | $10,969,078 | +10.7% | 246,953 | -0.3% | 0.01% | +33.3% |
| Q1 2022 | $9,908,536 | +8.8% | 247,811 | +9.4% | 0.01% | 0.0% |
| Q4 2021 | $9,111,000 | -48.1% | 226,438 | -47.5% | 0.01% | -57.1% |
| Q3 2021 | $17,555,000 | +73.2% | 431,549 | +93.3% | 0.01% | +75.0% |
| Q2 2021 | $10,137,000 | +13.1% | 223,235 | +3.8% | 0.01% | 0.0% |
| Q1 2021 | $8,964,000 | -8.7% | 215,017 | -6.5% | 0.01% | -11.1% |
| Q4 2020 | $9,818,000 | +375.2% | 229,874 | +192.4% | 0.01% | +350.0% |
| Q3 2020 | $2,066,000 | -1.1% | 78,629 | -2.8% | 0.00% | 0.0% |
| Q2 2020 | $2,088,000 | +32.6% | 80,868 | -7.6% | 0.00% | 0.0% |
| Q1 2020 | $1,575,000 | +3.3% | 87,562 | +1.8% | 0.00% | 0.0% |
| Q4 2019 | $1,525,000 | +12.7% | 86,034 | -3.3% | 0.00% | 0.0% |
| Q3 2019 | $1,353,000 | -11.8% | 89,003 | -0.3% | 0.00% | 0.0% |
| Q2 2019 | $1,534,000 | +15.8% | 89,295 | +8.5% | 0.00% | +100.0% |
| Q1 2019 | $1,325,000 | +17.2% | 82,307 | +6.5% | 0.00% | 0.0% |
| Q4 2018 | $1,131,000 | -23.7% | 77,297 | -5.3% | 0.00% | -50.0% |
| Q3 2018 | $1,483,000 | -88.8% | 81,602 | -89.6% | 0.00% | -85.7% |
| Q2 2018 | $13,241,000 | -11.5% | 784,901 | +2.7% | 0.01% | -17.6% |
| Q1 2018 | $14,970,000 | +3.1% | 764,139 | +6.7% | 0.02% | +6.2% |
| Q4 2017 | $14,516,000 | -2.4% | 716,482 | -16.4% | 0.02% | -11.1% |
| Q3 2017 | $14,879,000 | +14.7% | 856,575 | -15.3% | 0.02% | +12.5% |
| Q2 2017 | $12,968,000 | +518.1% | 1,011,449 | +524.7% | 0.02% | +433.3% |
| Q1 2017 | $2,098,000 | +20.7% | 161,904 | -8.0% | 0.00% | +50.0% |
| Q4 2016 | $1,738,000 | -14.5% | 175,907 | +4.5% | 0.00% | -33.3% |
| Q3 2016 | $2,033,000 | +29.5% | 168,378 | -7.5% | 0.00% | +50.0% |
| Q2 2016 | $1,570,000 | -8.5% | 182,009 | -1.8% | 0.00% | +100.0% |
| Q1 2016 | $1,715,000 | -32.7% | 185,264 | +26.0% | 0.00% | -50.0% |
| Q4 2015 | $2,549,000 | +29.1% | 147,060 | +0.0% | 0.00% | 0.0% |
| Q3 2015 | $1,974,000 | -34.5% | 147,002 | +10.1% | 0.00% | -50.0% |
| Q2 2015 | $3,015,000 | +206.7% | 133,534 | +94.1% | 0.00% | +300.0% |
| Q1 2015 | $983,000 | +51.7% | 68,788 | +2.4% | 0.00% | 0.0% |
| Q4 2014 | $648,000 | +4.9% | 67,170 | -1.1% | 0.00% | 0.0% |
| Q3 2014 | $618,000 | -6.5% | 67,919 | +1.6% | 0.00% | 0.0% |
| Q2 2014 | $661,000 | -23.6% | 66,861 | -1.8% | 0.00% | 0.0% |
| Q1 2014 | $865,000 | -15.5% | 68,056 | -0.4% | 0.00% | -50.0% |
| Q4 2013 | $1,024,000 | +31.3% | 68,328 | -3.3% | 0.00% | +100.0% |
| Q3 2013 | $780,000 | +33.6% | 70,652 | -3.9% | 0.00% | 0.0% |
| Q2 2013 | $584,000 | – | 73,533 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |